AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3949999 — intervention group
Group type: EXPERIMENTAL
Intervention: Judges with an extensive definition of 'clinical depression'
Number of subjects: 56
Study 3949999 — intervention group
Group type: EXPERIMENTAL
Intervention: Judges with both conditions (label and extensive definition)
Number of subjects: 56
Study 31248676 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine dosing interval less than 3 minutes
Number of subjects: 15909
Study 31248676 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine dosing interval 3 to less than 4 minutes
Number of subjects: 15909
Study 31248676 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine dosing interval 4 to less than 5 minutes
Number of subjects: 15909
Study 31248676 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine dosing interval greater than or equal to 5 minutes
Number of subjects: 15909
Study 28776276 — intervention group
Group type: EXPERIMENTAL
Intervention: High cash transfer
Number of subjects: 988
Study 28776276 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cash transfer
Number of subjects: 988
Study 28776276 — intervention group
Group type: COMPARATOR
Intervention: No cash control
Number of subjects: 988
Study 28122366 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive, Individualized, Person-Centered Management (CI-PCM) program
Number of subjects: 20
Study 28122366 — intervention group
Group type: COMPARATOR
Intervention: Usual community care (Control)
Number of subjects: 20
Study 25425373 — intervention group
Group type: COMPARATOR
Intervention: Standard arm - cervix visualized, no prespecified cervical length measurement
Number of subjects: 60
Study 25425373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential arm - 3 transabdominal cervical length measurements obtained, transvaginal sonography performed if images were inadequate or if any measurement was 3 cm or less
Number of subjects: 60
Study 25425373 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening transvaginal sonography arm - 3 transvaginal cervical length measurements obtained
Number of subjects: 60
Study 23719016 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji VII
Number of subjects: 57
Study 23719016 — intervention group
Group type: COMPARATOR
Intervention: Concise
Number of subjects: 57
Study 20809722 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestige disc prosthesis
Number of subjects: 541
Study 20809722 — intervention group
Group type: COMPARATOR
Intervention: Instrumented interbody fusion (Control)
Number of subjects: 541
Study 18394126 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (MCh)
Number of subjects: 113
Study 18394126 — intervention group
Group type: COMPARATOR
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 113
Study 18394126 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (MCh) and Adenosine 5'-monophosphate (AMP)
Number of subjects: 113
Study 16608131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) training
Number of subjects: 22
Study 16608131 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 22
Study 14696412 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural anesthesia and analgesia (Group A)
Number of subjects: 50
Study 14696412 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with postoperative i.v. analgesia (Group B)
Number of subjects: 50
Study 11095259 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (MEI) view
Number of subjects: 296
Study 11095259 — intervention group
Group type: COMPARATOR
Intervention: No imager view (Control)
Number of subjects: 296
Study 8151462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 50 mg/kg intramuscularly
Number of subjects: 6733
Study 8151462 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, 20 mg/kg/dose orally for six doses
Number of subjects: 6733
Study 8151462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 6733
Study 8151462 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 6733
Study 3048273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness training (CVR)
Number of subjects: 42
Study 3048273 — intervention group
Group type: COMPARATOR
Intervention: Flexibility exercises (FLEX)
Number of subjects: 42
Study 29183095 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery volumetric flow
Number of subjects: 61
Study 29183095 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery resistance index (RI)
Number of subjects: 61
Study 29183095 — intervention group
Group type: COMPARATOR
Intervention: Smoking status
Number of subjects: 61
Study 28687178 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed to mandated abortion counseling via a standardized video
Number of subjects: 46
Study 28687178 — intervention group
Group type: COMPARATOR
Intervention: Unexposed to mandated abortion counseling
Number of subjects: 46
Study 28687178 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling for participant income category
Number of subjects: 46
Study 29258980 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended care self-management program 'Partner in Balance' (PiB) combining face-to-face coaching with tailored web-based modules.
Number of subjects: 49
Study 29258980 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended care self-management program 'Partner in Balance' (PiB)
Number of subjects: 49
Study 23715625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg
Number of subjects: 643
Study 23715625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 21935965 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release zaleplon 15 mg (SKP-1041A, SKP-1041B, SKP-1041C)
Number of subjects: 42
Study 21935965 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release zaleplon 15 mg (SKP-1041A, SKP-1041B)
Number of subjects: 42
Study 21935965 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release zaleplon 10 mg
Number of subjects: 42
Study 21935965 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release zaleplon 15 mg (SKP-1041)
Number of subjects: 42
Study 21935965 — intervention group
Group type: EXPERIMENTAL
Intervention: SKP-1041B
Number of subjects: 42
Study 20205026 — intervention group
Group type: EXPERIMENTAL
Intervention: pedometer and pretest (n = 16)
Number of subjects: 63
Study 20205026 — intervention group
Group type: EXPERIMENTAL
Intervention: pedometer and no pretest (n = 16)
Number of subjects: 63
Study 20205026 — intervention group
Group type: COMPARATOR
Intervention: no pedometer and pretest (n = 15)
Number of subjects: 63
Study 20205026 — intervention group
Group type: COMPARATOR
Intervention: no pedometer and no pretest (n = 16)
Number of subjects: 63
Study 20205026 — intervention group
Group type: EXPERIMENTAL
Intervention: pedometer use
Number of subjects: 63
Study 17354160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam (various regimens)
Number of subjects: 884
Study 17354160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 3 days regimen
Number of subjects: 884
Study 17354160 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 7 days regimen
Number of subjects: 884
Study 17354160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 884
Study 15279475 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond FL combined with Prodigy (O-FL/Pro)
Number of subjects: 150
Study 15279475 — intervention group
Group type: EXPERIMENTAL
Intervention: PermaQuick combined with Amelogen Hybrid (PMQ/A-Hy)
Number of subjects: 150
Study 15279475 — intervention group
Group type: EXPERIMENTAL
Intervention: PermaQuick combined with Amelogen Microfill (PMQ/A-Mi)
Number of subjects: 150
Study 15279475 — intervention group
Group type: COMPARATOR
Intervention: Comparison of microfilled and hybrid composites
Number of subjects: 150
Study 11529537 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) at a dose of 0.15 IU kg(-1) per day for 3 years (Group A: discontinuous, Group B: control for 1 year then continuous, Group C: continuous)
Number of subjects: 37
Study 11529537 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone treatment (GH) (Group A: discontinuous, Group B: continuous after 1 year, Group C: continuous)
Number of subjects: 37
Study 11529537 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) (Group A: discontinuous, Group B: continuous, Group C: continuous)
Number of subjects: 37
Study 11529537 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) (Group A: discontinuous)
Number of subjects: 37
Study 9555791 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid-based lipid emulsion (Omegavenous; 200 ml/day with 4.2 gm of both EPA and DHA)
Number of subjects: 83
Study 9555791 — intervention group
Group type: COMPARATOR
Intervention: Conventional omega-6-lipid emulsion (Lipovenous; EPA+DHA < 0.1 gm/100 ml)
Number of subjects: 83
Study 7602351 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐Hu‐EPO 150 IU/kg three times per week
Number of subjects: 36
Study 7602351 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐Hu‐EPO 300 IU/kg three times per week
Number of subjects: 36
Study 7602351 — intervention group
Group type: COMPARATOR
Intervention: Control group (no r‐Hu‐EPO)
Number of subjects: 36
Study 2337211 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (100 micrograms)
Number of subjects: 30
Study 2337211 — intervention group
Group type: COMPARATOR
Intervention: Control (2 ml saline with 0.5% bupivacaine)
Number of subjects: 30
Study 204183 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: diet for 6 weeks, then diet plus clofibrate for 18 weeks
Number of subjects: 146
Study 204183 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: diet treatment from a clinic nutritionist with cooperation of the subject's private physician
Number of subjects: 146
Study 204183 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: referral for treatment by a private physician
Number of subjects: 146
Study 204183 — intervention group
Group type: COMPARATOR
Intervention: Group D: no intervention
Number of subjects: 146
Study 30870054 — intervention group
Group type: EXPERIMENTAL
Intervention: No heavy drinking days (NHDD)
Number of subjects: 888
Study 30870054 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent heavy drinking days (PHDD)
Number of subjects: 888
Study 30870054 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink size misestimation
Number of subjects: 888
Study 28032908 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus plantarum and Lactobacillus brevis)
Number of subjects: 20
Study 28032908 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 20
Study 25458662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (exercise training, multidisciplinary care through a nurse practitioner‐led CKD clinic)
Number of subjects: 83
Study 23596811 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp electroacupuncture
Number of subjects: 233
Study 23596811 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome differentiation
Number of subjects: 233
Study 23596811 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine (drug group)
Number of subjects: 233
Study 21550374 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV), Haemophilus influenzae type b conjugate vaccine, and tetanus toxoid
Number of subjects: 0
Study 21550374 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV at 7 or 17 weeks and second dose at 3 years of age
Number of subjects: 0
Study 21550374 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vaccination
Number of subjects: 0
Study 21550374 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV revaccination at 3 years of age
Number of subjects: 0
Study 21550374 — intervention group
Group type: COMPARATOR
Intervention: Tetanus toxoid alone
Number of subjects: 0
Study 19765879 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm use for HIV prevention
Number of subjects: 2316
Study 19765879 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert use of diaphragm
Number of subjects: 2316
Study 19765879 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of disclosure levels
Number of subjects: 2316
Study 16360855 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐mm self‐reinforced polylactate (PLLDL 70/30) biodegradable screws (group B)
Number of subjects: 69
Study 16360855 — intervention group
Group type: COMPARATOR
Intervention: 2‐mm titanium screws (group T)
Number of subjects: 69
Study 16360855 — intervention group
Group type: COMPARATOR
Intervention: Comparison of stability between groups
Number of subjects: 69
Study 15624548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 22
Study 11768322 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day alpha-tocopherol for 14 days
Number of subjects: 48
Study 11768322 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g of ascorbic acid administered intravenously prior to induction
Number of subjects: 48
Study 11768322 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g of ascorbic acid administered in the cardioplegic solution
Number of subjects: 48
Study 11768322 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 9236545 — intervention group
Group type: EXPERIMENTAL
Intervention: Families of affectively ill juveniles
Number of subjects: 180
Study 9236545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers of affectively ill youths
Number of subjects: 180
Study 9236545 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives of affectively ill probands
Number of subjects: 180
Study 9236545 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial illness patterns
Number of subjects: 180
Study 9236545 — intervention group
Group type: EXPERIMENTAL
Intervention: Families of depressed youngsters
Number of subjects: 180
Study 8175843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Hastings hemiarthroplasty
Number of subjects: 20
Study 8175843 — intervention group
Group type: COMPARATOR
Intervention: Uncemented Austin‐Moore hemiarthroplasty
Number of subjects: 20
Study 3148470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg i.m.
Number of subjects: 0
Study 3148470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 90 mg i.m.
Number of subjects: 0
Study 3148470 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg i.m.
Number of subjects: 0
Study 29301824 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 (20 μg/day for 13 weeks, then 60 μg/day for 26 weeks)
Number of subjects: 60
Study 27000103 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 166
Study 25895497 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 μg/kg
Number of subjects: 90
Study 25895497 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 90
Study 22638548 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c increase by 1 percentage point
Number of subjects: 8252
Study 22638548 — intervention group
Group type: COMPARATOR
Intervention: HbA1c ≤ 6.4% (≤ 46 mmol/l)
Number of subjects: 8252
Study 21831757 — intervention group
Group type: COMPARATOR
Intervention: Raffinose diet
Number of subjects: 12
Study 21831757 — intervention group
Group type: COMPARATOR
Intervention: Chickpea diet
Number of subjects: 12
Study 21831757 — intervention group
Group type: EXPERIMENTAL
Intervention: Control diet
Number of subjects: 12
Study 18261561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 20
Study 18261561 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CNI)
Number of subjects: 20
Study 16185966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis and portal hypertension patients (n=37)
Number of subjects: 37
Study 16185966 — intervention group
Group type: COMPARATOR
Intervention: Control patients (n=34)
Number of subjects: 37
Study 16185966 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of patients with and without PHE
Number of subjects: 37
Study 12933387 — intervention group
Group type: EXPERIMENTAL
Intervention: N(2)O/air
Number of subjects: 10
Study 12933387 — intervention group
Group type: EXPERIMENTAL
Intervention: air/N(2)O
Number of subjects: 10
Study 12933387 — intervention group
Group type: COMPARATOR
Intervention: propofol anesthesia
Number of subjects: 10
Study 10684784 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 160
Study 10684784 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 600-800 mg
Number of subjects: 160
Study 10684784 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 160
Study 8788104 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvel
Number of subjects: 80
Study 8788104 — intervention group
Group type: COMPARATOR
Intervention: Vasculour‐II
Number of subjects: 80
Study 1290731 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 348
Study 1290731 — intervention group
Group type: COMPARATOR
Intervention: Continuing medical treatment
Number of subjects: 348
Study 6394209 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 6394209 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 30738387 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of choroidal collaterals (collateral-positive group)
Number of subjects: 36
Study 30738387 — intervention group
Group type: COMPARATOR
Intervention: Absence of choroidal collaterals (collateral-negative group)
Number of subjects: 36
Study 29782035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet of rosuvastatin-ezetimibe
Number of subjects: 24
Study 29782035 — intervention group
Group type: COMPARATOR
Intervention: Separate tablets of rosuvastatin and ezetimibe
Number of subjects: 24
Study 27161611 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (single dose prior to coronary angiography)
Number of subjects: 117
Study 27161611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 24442858 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin and cyclosporine A (CSA)
Number of subjects: 50
Study 24442858 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched sibling donor hematopoietic stem cell transplantation
Number of subjects: 50
Study 24442858 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA and growth factors
Number of subjects: 50
Study 23106871 — intervention group
Group type: EXPERIMENTAL
Intervention: TL-pulsed DC-CIK cells immunotherapy
Number of subjects: 137
Study 23106871 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-α immunotherapy
Number of subjects: 137
Study 23106871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postoperative adjuvant therapy)
Number of subjects: 137
Study 19544816 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion with Al2O3 particles
Number of subjects: 240
Study 19544816 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation
Number of subjects: 240
Study 19544816 — intervention group
Group type: COMPARATOR
Intervention: Untreated surfaces
Number of subjects: 240
Study 19544816 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal Primer (Alloy Primer, Metal Primer II, Metaltite)
Number of subjects: 240
Study 19544816 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion with Al2O3 particles and application of metal primers
Number of subjects: 240
Study 17284626 — intervention group
Group type: EXPERIMENTAL
Intervention: GH plus GnRHa (n=17)
Number of subjects: 32
Study 14755010 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/LV alone (arm A)
Number of subjects: 463
Study 14755010 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin alone (arm B)
Number of subjects: 463
Study 14755010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5‐FU/LV (arm C)
Number of subjects: 463
Study 11216931 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive individuals
Number of subjects: 482
Study 11216931 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative individuals
Number of subjects: 482
Study 9744142 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbohaler 400 micrograms once daily
Number of subjects: 167
Study 9744142 — intervention group
Group type: COMPARATOR
Intervention: Budesonide Turbohaler 200 micrograms twice daily
Number of subjects: 167
Study 7848948 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg intramuscularly before and after surgery
Number of subjects: 48
Study 7848948 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 48
Study 3139698 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG
Number of subjects: 91
Study 3139698 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone and oestradiol valerate
Number of subjects: 91
Study 3139698 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist and HMG
Number of subjects: 91
Study 3139698 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate‐HMG
Number of subjects: 91
Study 30297663 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day n-3 LCPUFA as HiDHA™ tuna oil
Number of subjects: 53
Study 30297663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 g/day n-3 LCPUFA as HiDHA™ tuna oil
Number of subjects: 53
Study 30297663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 g/day n-3 LCPUFA as HiDHA™ tuna oil
Number of subjects: 53
Study 30297663 — intervention group
Group type: COMPARATOR
Intervention: 0 g/day n-3 LCPUFA (placebo - Sunola oil)
Number of subjects: 53
Study 26507926 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical eflornithine applied twice daily for 6 months
Number of subjects: 22
Study 26507926 — intervention group
Group type: COMPARATOR
Intervention: No eflornithine treatment (control)
Number of subjects: 22
Study 25546177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sono-electro-magnetic therapy
Number of subjects: 60
Study 25546177 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 60
Study 22382382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 226
Study 22382382 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 226